Traws Pharma
TRAW
23 hedge funds and large institutions have $2.19M invested in Traws Pharma in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
110% more capital invested
Capital invested by funds: $1.04M → $2.19M (+$1.15M)
0.08% more ownership
Funds ownership: 0.27% → 0.35% (+0.08%)
4% less funds holding
Funds holding: 24 → 23 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$170K |
| 2 |
Two Sigma Advisers
New York
|
+$125K |
| 3 |
Renaissance Technologies
New York
|
+$96.7K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$91.8K |
| 5 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$16.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$14.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9.63K |
| 4 |
Jane Street
New York
|
-$7.53K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.83K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jane Street
New York
| – | -$7.53K | -412 | Closed |
|
|
LFG
27
Larson Financial Group
St Louis,
Missouri
| – | -$48 | -3 | Closed |
|
TRAW Hedge Fund Activity: Q2 2023 in Review
23 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2023, worth a combined $2.19M — up 110% from $1.04M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TRAW and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $170K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $20.7K sold.
- 23 institutional investors held Traws Pharma (TRAW) as of Q2 2023, down from 24 in Q1 2023.
- Funds reported $2.19M of Traws Pharma stock for Q2 2023, up 110% quarter-over-quarter.
- 4 funds opened new Traws Pharma positions in Q2 2023 and 5 closed out, a net change of -1 holder.
- The largest Traws Pharma buyer in Q2 2023 was Two Sigma Investments, an estimated $170K added.
- The largest Traws Pharma seller in Q2 2023 was Susquehanna International Group, an estimated $20.7K sold.
Based on aggregated 13F filings for Q2 2023.